berberine has been researched along with Dyslipidemia in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of berberine (BBR) plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia." | 9.41 | Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. ( González-Ortiz, M; León-Martínez, JM; Martínez-Abundis, E; Pérez-Rubio, KG, 2021) |
| "Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia." | 9.13 | Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. ( Hong, J; Huo, L; Li, X; Liu, W; Ning, G; Ren, G; Wang, M; Wu, P; Yang, J; Zhang, Y; Zhu, N; Zou, D, 2008) |
| "The aim of this study was to analyze the efficacy of berberine taken alone or in other formulations (with silymarin or other mixtures) on dyslipidemia through a systematic review of the literature and a meta-analysis." | 9.05 | Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis. ( Amatori, S; Bertuccioli, A; Moricoli, S; Rocchi, MBL; Sisti, D; Vici, G, 2020) |
| "To evaluate the clinical efficacy and safety of berberine in the treatment of dyslipidemia." | 9.05 | [Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia]. ( DU, YW; Wu, SX; Yang, HM; Yang, YY; Zhao, Y, 2020) |
| "This study aimed to evaluate the cholesterol-lowering effect of epiberberine in dyslipidemia Syrian golden hamsters induced by high fat and high cholesterol (HFHC) diet and its regulation mechanism on some key genes involved in cholesterol metabolism." | 7.83 | Epiberberine reduces serum cholesterol in diet-induced dyslipidemia Syrian golden hamsters via network pathways involving cholesterol metabolism. ( Feng, M; Hu, YR; Li, XG; Ma, H; Ye, XL; Zou, ZY, 2016) |
| " Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation." | 7.78 | Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. ( Sun, ZL; Xiao, HB; Zhang, DS; Zhang, HB, 2012) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 7.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "Berberine is a nutraceutical that can improve lipid metabolism." | 7.01 | Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. ( Blais, JE; Huang, X; Zhao, JV, 2023) |
| "Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide." | 7.01 | Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial. ( Du, YW; Ren, DW; Wang, J; Wang, YX; Wu, SX; Yang, BL; Yang, HM; Yang, YY; Zhang, YY; Zhao, Y; Zhou, HM, 2021) |
| "BBR improved NAFLD by inhibiting glucogenesis and comprehensively regulating lipid metabolism, and its effect on inhibiting hepatic lipogenesis was much stronger." | 5.46 | Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017) |
| "To evaluate the effect of berberine (BBR) plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia." | 5.41 | Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. ( González-Ortiz, M; León-Martínez, JM; Martínez-Abundis, E; Pérez-Rubio, KG, 2021) |
| " The present review analysed the literature in the field of nutraceuticals for the treatment of dyslipidemia, focusing on resveratrol, red yeast rice, berberine, and plant sterols, which are among the nutraceuticals with the greatest formulation problems, highlighting bioavailability and the most suitable formulations." | 5.22 | Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. ( Colletti, A; Cravotto, G; Fratter, A; Pellizzato, M, 2022) |
| "A comprehensive metabonomic method, in combination with fingerprint analysis and target analysis, was performed to reveal potential mechanisms of berberine action in the treatment of patients with type 2 diabetes and dyslipidemia." | 5.14 | Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. ( Chen, J; Gu, W; Gu, Y; Hong, J; Li, X; Lu, X; Ning, G; Shi, X; Xu, G; Zhang, Y, 2010) |
| "Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia." | 5.13 | Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. ( Hong, J; Huo, L; Li, X; Liu, W; Ning, G; Ren, G; Wang, M; Wu, P; Yang, J; Zhang, Y; Zhu, N; Zou, D, 2008) |
| "Berberine (BERB) and a combination (COMB) of berberine (CAS 2086-83-1) with policosanol (CAS 557-61-9), red yeast extract (containing monacolin, CAS 557-61-9), folic acid and astaxanthin were orally administered daily for 4 weeks to 40 subjects with moderate dyslipidemias divided in two parallel groups each of 20 subjects." | 5.12 | Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. ( Cicero, AF; Rovati, LC; Setnikar, I, 2007) |
| "The aim of this study was to analyze the efficacy of berberine taken alone or in other formulations (with silymarin or other mixtures) on dyslipidemia through a systematic review of the literature and a meta-analysis." | 5.05 | Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis. ( Amatori, S; Bertuccioli, A; Moricoli, S; Rocchi, MBL; Sisti, D; Vici, G, 2020) |
| "To evaluate the clinical efficacy and safety of berberine in the treatment of dyslipidemia." | 5.05 | [Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia]. ( DU, YW; Wu, SX; Yang, HM; Yang, YY; Zhao, Y, 2020) |
| "This study aimed to evaluate the cholesterol-lowering effect of epiberberine in dyslipidemia Syrian golden hamsters induced by high fat and high cholesterol (HFHC) diet and its regulation mechanism on some key genes involved in cholesterol metabolism." | 3.83 | Epiberberine reduces serum cholesterol in diet-induced dyslipidemia Syrian golden hamsters via network pathways involving cholesterol metabolism. ( Feng, M; Hu, YR; Li, XG; Ma, H; Ye, XL; Zou, ZY, 2016) |
| " Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation." | 3.78 | Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. ( Sun, ZL; Xiao, HB; Zhang, DS; Zhang, HB, 2012) |
| " Recently, it has been demonstrated that berberine (BBR) exerts antiobesity and antidiabetic effects in obese and diabetic rodent models through the activation of AMPK in peripheral tissues." | 3.75 | Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. ( Cha, SH; Choe, SS; Jeong, HW; Kim, JB; Kim, WS; Lane, MD; Lee, KU; Lee, MR; Lee, YS; Oh, GT; Park, HS, 2009) |
| "Berberine is a nutraceutical that can improve lipid metabolism." | 3.01 | Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. ( Blais, JE; Huang, X; Zhao, JV, 2023) |
| "Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease and a leading cause of death worldwide." | 3.01 | Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial. ( Du, YW; Ren, DW; Wang, J; Wang, YX; Wu, SX; Yang, BL; Yang, HM; Yang, YY; Zhang, YY; Zhao, Y; Zhou, HM, 2021) |
| "Berberine is a bioactive isoquinoline alkaloid compound extracted from various medicinal plants, such as Barberry." | 2.82 | Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. ( Hashemy, SI; Nourizadeh, N; Saburi, E; Vazifeh Mostaan, L, 2022) |
| "Nutraceuticals (NUT) are forms of compounds with biological activity commonly used to improve health in dosage largely exceeding those obtainable in food." | 2.80 | Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. ( Esposito, G; Izzo, R; Manzi, MV; Rozza, F; Santoro, M; Schiattarella, GG; Serino, F; Stabile, E; Trimarco, B; Trimarco, V, 2015) |
| " No significant differences were found between groups in terms of incidence of adverse events (RR = 0." | 2.58 | Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. ( Ju, J; Li, J; Lin, Q; Xu, H, 2018) |
| "Dyslipidemia is a major independent and reversible risk factor for these diseases: it is estimated that a reduction of 1 mmol/l (38 mg/dl) of LDL cholesterol is associated with a risk of developing a cardiovascular complication reduced by 25%, a reduction potentially achieved by life-style improvement associated to adequate dietary supplementation with bioactive substances." | 2.53 | Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data. ( Cicero, AF; Colletti, A, 2016) |
| "Non‑alcoholic fatty liver disease (NAFLD), which affects approximately one‑third of the general population, has become a global health problem." | 1.48 | Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. ( Gao, S; Huang, D; Huang, J; Tong, P; Wang, Y; Wu, X; Yue, Y; Zhao, J, 2018) |
| "BBR improved NAFLD by inhibiting glucogenesis and comprehensively regulating lipid metabolism, and its effect on inhibiting hepatic lipogenesis was much stronger." | 1.46 | Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017) |
| " As apoE is a potent ligand for the LDL receptor, we next evaluated the effects of TOR in combination with the LDL-lowering drug berberine, which upregulates LDL receptor expression in dyslipidemic hamsters." | 1.39 | Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. ( Briand, F; Muzotte, E; Sulpice, T; Thieblemont, Q, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 19 (65.52) | 24.3611 |
| 2020's | 7 (24.14) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, SP | 1 |
| Sashidhara, KV | 1 |
| Nourizadeh, N | 1 |
| Vazifeh Mostaan, L | 1 |
| Saburi, E | 1 |
| Hashemy, SI | 1 |
| Colletti, A | 4 |
| Fratter, A | 3 |
| Pellizzato, M | 3 |
| Cravotto, G | 3 |
| Blais, JE | 1 |
| Huang, X | 1 |
| Zhao, JV | 1 |
| Bertuccioli, A | 1 |
| Moricoli, S | 1 |
| Amatori, S | 1 |
| Rocchi, MBL | 1 |
| Vici, G | 1 |
| Sisti, D | 1 |
| Zhao, Y | 2 |
| Yang, YY | 2 |
| DU, YW | 2 |
| Yang, HM | 2 |
| Wu, SX | 2 |
| León-Martínez, JM | 1 |
| Martínez-Abundis, E | 1 |
| González-Ortiz, M | 1 |
| Pérez-Rubio, KG | 1 |
| Yang, BL | 1 |
| Ren, DW | 1 |
| Zhou, HM | 1 |
| Wang, J | 1 |
| Wang, YX | 1 |
| Zhang, YY | 1 |
| Sahebkar, A | 1 |
| Watts, GF | 1 |
| Marchitto, N | 1 |
| Sindona, F | 1 |
| Fabrizio, A | 1 |
| Mauti, M | 1 |
| Andreozzi, S | 1 |
| Dalmaso, S | 1 |
| Raimondi, G | 1 |
| Di Pierro, F | 1 |
| Putignano, P | 1 |
| Villanova, N | 1 |
| Zhao, J | 1 |
| Wang, Y | 1 |
| Wu, X | 1 |
| Tong, P | 1 |
| Yue, Y | 1 |
| Gao, S | 1 |
| Huang, D | 1 |
| Huang, J | 1 |
| Ju, J | 1 |
| Li, J | 1 |
| Lin, Q | 1 |
| Xu, H | 1 |
| Guo, HH | 1 |
| Feng, CL | 1 |
| Zhang, WX | 1 |
| Luo, ZG | 1 |
| Zhang, HJ | 1 |
| Zhang, TT | 1 |
| Ma, C | 1 |
| Zhan, Y | 1 |
| Li, R | 1 |
| Wu, S | 1 |
| Abliz, Z | 1 |
| Li, C | 1 |
| Li, XL | 1 |
| Ma, XL | 1 |
| Wang, LL | 1 |
| Zheng, WS | 1 |
| Han, YX | 1 |
| Jiang, JD | 1 |
| Trimarco, V | 1 |
| Izzo, R | 1 |
| Stabile, E | 1 |
| Rozza, F | 1 |
| Santoro, M | 1 |
| Manzi, MV | 1 |
| Serino, F | 1 |
| Schiattarella, GG | 1 |
| Esposito, G | 1 |
| Trimarco, B | 1 |
| Luthra, A | 2 |
| Misra, A | 2 |
| Mudur, G | 1 |
| Zou, ZY | 1 |
| Hu, YR | 1 |
| Ma, H | 1 |
| Feng, M | 1 |
| Li, XG | 1 |
| Ye, XL | 1 |
| Cicero, AF | 2 |
| Jain, M | 1 |
| Jani, RH | 1 |
| Pareek, A | 1 |
| Chandurkar, N | 1 |
| Zhao, L | 1 |
| Cang, Z | 1 |
| Sun, H | 1 |
| Nie, X | 1 |
| Wang, N | 1 |
| Lu, Y | 1 |
| Kim, WS | 1 |
| Lee, YS | 1 |
| Cha, SH | 1 |
| Jeong, HW | 1 |
| Choe, SS | 1 |
| Lee, MR | 1 |
| Oh, GT | 1 |
| Park, HS | 1 |
| Lee, KU | 1 |
| Lane, MD | 1 |
| Kim, JB | 1 |
| Gu, Y | 1 |
| Zhang, Y | 2 |
| Shi, X | 1 |
| Li, X | 2 |
| Hong, J | 2 |
| Chen, J | 1 |
| Gu, W | 1 |
| Lu, X | 1 |
| Xu, G | 1 |
| Ning, G | 2 |
| Xiao, HB | 1 |
| Sun, ZL | 1 |
| Zhang, HB | 1 |
| Zhang, DS | 1 |
| Briand, F | 1 |
| Thieblemont, Q | 1 |
| Muzotte, E | 1 |
| Sulpice, T | 1 |
| Rovati, LC | 1 |
| Setnikar, I | 1 |
| Zou, D | 1 |
| Liu, W | 1 |
| Yang, J | 1 |
| Zhu, N | 1 |
| Huo, L | 1 |
| Wang, M | 1 |
| Wu, P | 1 |
| Ren, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial to Evaluate the Effects of Two Different Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve in Hypercholesterolemic Patients at Moderate Cardiovascular Risk[NCT02969070] | 28 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk[NCT02898805] | 600 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The Effect of Berberine on the Secretion of Incretin in Normal Man[NCT05947370] | Early Phase 1 | 16 participants (Actual) | Interventional | 2022-10-12 | Completed | ||
| Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for berberine and Dyslipidemia
| Article | Year |
|---|---|
Lipid lowering agents of natural origin: An account of some promising chemotypes.
Topics: Animals; Biological Products; Dyslipidemias; Humans; Hypolipidemic Agents | 2017 |
Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review.
Topics: Anti-Inflammatory Agents; Antioxidants; Aryldialkylphosphatase; Atherosclerosis; Berberine; Choleste | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.
Topics: Berberine; Dietary Supplements; Dyslipidemias; Humans; Lipids; Phytosterols | 2022 |
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Topics: Adult; Apolipoproteins; Berberine; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; F | 2023 |
Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis.
Topics: Berberine; Cholesterol; Controlled Clinical Trials as Topic; Dyslipidemias; Humans; Hydroxymethylglu | 2020 |
[Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia].
Topics: Berberine; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Randomized Controlled Trials as Topi | 2020 |
Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications?
Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Lipid Metabolism; Lipids; Non- | 2017 |
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.
Topics: Berberine; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Lipids; Randomized Controlled | 2018 |
Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data.
Topics: Berberine; Biological Products; Cholesterol; Clinical Trials as Topic; Dietary Supplements; Drug The | 2016 |
6 trials available for berberine and Dyslipidemia
| Article | Year |
|---|---|
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial.
Topics: Adult; Berberine; Bezafibrate; Dyslipidemias; Humans; Lipids; Middle Aged; Pilot Projects; Triglycer | 2021 |
Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial.
Topics: Berberine; Data Management; Double-Blind Method; Drugs, Chinese Herbal; Dyslipidemias; Humans; Medic | 2021 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
Topics: Aged; Berberine; Biomarkers; Blood Glucose; Cross-Over Studies; Dietary Supplements; Double-Blind Me | 2015 |
Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics.
Topics: Aged; Berberine; Chromatography, Liquid; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemi | 2010 |
Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation.
Topics: Anticholesteremic Agents; Berberine; Cholesterol; Dietary Supplements; Drug Combinations; Dyslipidem | 2007 |
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
Topics: Adult; Aged; Berberine; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidem | 2008 |
14 other studies available for berberine and Dyslipidemia
| Article | Year |
|---|---|
Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome.
Topics: Berberine; Biological Products; Cassia; Dietary Supplements; Dyslipidemias; Fatty Alcohols; Humans; | 2018 |
Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia.
Topics: Aged; Berberine; Biological Products; Diabetes Mellitus; Dietary Supplements; Dyslipidemias; Female; | 2018 |
Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling.
Topics: Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Animals; Aspartate Aminotransferases; Be | 2018 |
Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.
Topics: Animals; Berberine; Caco-2 Cells; Cardiovascular Diseases; Dyslipidemias; Hep G2 Cells; Humans; Hypo | 2019 |
The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2015 |
Indian endocrinologists start debate on diabetes drug.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2015 |
Epiberberine reduces serum cholesterol in diet-induced dyslipidemia Syrian golden hamsters via network pathways involving cholesterol metabolism.
Topics: Adipose Tissue; Animals; Berberine; Bile Acids and Salts; Biological Transport; Cholesterol; Cholest | 2016 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Drug approvals in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Drug approvals in India - Authors' reply.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxych | 2016 |
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Carbohydrate Metabolism; Diet, High-Fat | 2017 |
Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.
Topics: Adenylate Kinase; Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Drug Evaluat | 2009 |
Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation.
Topics: Animals; Berberine; Dinoprost; Dyslipidemias; Female; Inflammation; Interferon-gamma; Interleukin-1a | 2012 |
Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Topics: Animals; Berberine; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Choleste | 2013 |